Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for treating coronavirus infections

A virus infection and composition technology, applied in the direction of antiviral agents, active ingredients of hydroxyl compounds, drug delivery, etc., can solve the problems of evaluation, no virus, etc.

Active Publication Date: 2021-04-20
PHOENIX BIOTECH INC
View PDF73 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0020] Oleandrin has shown anti-HIV activity but has not been evaluated against many viruses
The triterpenes oleanolic acid, betulinic acid, and ursolic acid have been reported to exhibit varying levels of antiviral activity but have not been evaluated against many viruses
Few, if any, free virions are produced, and although virus is present in genital secretions, there is usually no detectable virus in plasma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating coronavirus infections
  • Methods and compositions for treating coronavirus infections
  • Methods and compositions for treating coronavirus infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 15

[0130] Example 15 provides a detailed description of the in vitro assay used to evaluate TM (hot water extract of oleander) and PBI-05204 (supercritical fluid (SCF) extract of oleander) against Ebola virus ( Figure 1-2 ) and Marburg virus ( Figure 3-4 ) infection, both Ebola virus and Marburg virus are filoviruses.

[0131] The hot water extract can be administered orally, sublingually, subcutaneously, and intramuscularly. One embodiment is available under the trade name ANVIRZEL TM (Nerium Biotechnology, Inc., San Antonio, TX; Salud Integral Medical Clinic, Tegucigalpa, Honduras; www.saludintegral.com; www.anvirzel.com) is available as a liquid dosage form. For sublingual administration, typical dosing regimens are 1.5 mL per day or three 0.5 mL doses per day. For injection administration, a typical dosing regimen is about 1 to about 2 mL / day, or about 0.1 to about 0.4 ml / m 2 / day for about 1 week to about 6 months or longer, or about 0.4 to about 0.8ml / m 2 / day for ab...

Embodiment 6

[0133]Example 6 provides a detailed description of the in vitro assay used to evaluate the efficacy of cardiac glycosides in the treatment of Zika virus (a flavivirus) infection. In the presence of oleandrin ( Figure 5 ) or digoxin ( Figure 6 ), Vero E6 cells were infected with Zika virus (ZIKV PRVABC59 strain) at an MOI of 0.2. Cells were incubated with virus and cardiac glycosides for 1 hour, after which time the inoculum and unabsorbed cardiac glycosides (if present) were removed. Cells were submerged in fresh medium and incubated for 48 hours before being fixed with formalin and stained for ZIKV infection. The data demonstrate that both cardiac glycosides have antiviral activity against Zika virus; however, oleandrin exhibited a higher (almost 8-fold greater) antiviral activity than digoxin.

Embodiment 14

[0134] Example 14 provides a detailed description of the experiments used to evaluate the antiviral activity of the test compositions against Zika virus and Dengue virus. The data demonstrate that oleandrin shows efficacy against Zika virus and Dengue virus.

[0135] Figure 7 A graph summarizing the in vitro dose-response antiviral activity of various compositions (oleandrin, digoxin, and PBI-05204) against Ebola virus (EBOV) in Vero E6 cells. Figure 8 A graph summarizing the in vitro dose-response antiviral activity of various compositions (oleandrin, digoxin, and PBI-05204) against Marburg virus (MARV) in Vero E6 cells is depicted. Figure 9 To depict a graph summarizing the in vitro cell survival of VeroE6 cells in the presence of various compositions (oleandrin, digoxin and PBI-05204). for Figure 7-8 , exposing the host cell to the composition prior to infection with the virus. EBOV / Kik ( Figure 7 , MOI=1) or MARV / Ci67 ( Figure 8 , MOI=1) to infect Vero E6 cells...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to View More

Abstract

Provided is a method for treating a viral infection such as a viral infection caused by a coronaviridae virus, for example. Compositions having at least oleandrin are used in the treatment of viral infections.

Description

[0001] incorporated by reference [0002] Pursuant to 37 CFR 1.52(e)(5), this application contains a Sequence Listing, which has been filed in electronic format via EFS, which is hereby incorporated by reference. The sequence information contained in the electronic file named PBI22PCT9_SEQ_ST25.txt, 1 KB in size, created on July 10, 2020 using Patent-in 3.5.1 and Checker 4.4.6, is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates to antiviral compositions and their use in the treatment of Arenaviridae, Bunyaviridae, Flaviviridae, Togaviridae infections in mammals , Paramyxoviridae infection, Retroviridae infection, Coronaviridae infection, or Filoviridae infection. Some embodiments relate to the treatment of hemorrhagic viral infections. Background technique [0004] Nerium oleander, a member of the Nerium species, is an ornamental plant widely distributed in subtropical Asia, the southwestern United States, and the Me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61K45/06A61P31/14A61P31/12
CPCA61K31/7048A61K45/06A61P31/14A61P31/12A61K36/24A61K2300/00A61K31/047A61K31/19A61K31/56A61K31/7084A61K31/14A61K9/006
Inventor R·A·纽曼O·C·阿丁顿R·欧比索
Owner PHOENIX BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com